Atosiban Impurity F is a defined related substance formed during atosiban synthesis or degradation. Structural deviations modify conformational preferences and chromatographic retention. Researchers use it to validate specificity in analytical methods and to understand degradation pathways. Applications include impurity profiling, stability testing, and peptide-process optimization.
CAT No: Z10-101-221
Synonyms/Alias:(5-amino-2-((S)-1-(((R)-3-(4-ethoxyphenyl)-2-(3-mercaptopropanamido)propanoyl)-L-isoleucyl-L-threonyl-L-asparaginyl-L-cysteinyl)pyrrolidine-2-carboxamido)pentanoyl)glycine; 2-((S)-5-amino-2-((S)-1-((2R,5S,8S,11S,14R)-5-(2-amino-2-oxoethyl)-11-((S)-sec-butyl)-14-(4-ethoxybenzyl)-8-((R)-1-hydroxyethyl)-18-mercapto-2-(mercaptomethyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaoctadecan-1-oyl)pyrrolidine-2-carboxamido)pentanamido)acetic acid
Atosiban impurity F is a small-molecule organic compound that arises as a structurally related byproduct during the synthesis or degradation of the peptide drug atosiban. As a chemically defined impurity, it plays a critical role in pharmaceutical quality control, process validation, and analytical method development. Its presence is of significant interest in both research and industrial settings, where a thorough understanding of synthesis-related byproducts is essential for ensuring the integrity and safety of peptide-based therapeutics. The compound's availability as a reference material supports a range of scientific and technical applications, particularly in the context of impurity profiling and regulatory-driven studies.
Impurity profiling: The use of atosiban impurity F as a reference standard is integral to the identification and quantification of related substances in pharmaceutical formulations. By enabling precise detection of this specific impurity, laboratories can assess the purity of atosiban batches, monitor manufacturing consistency, and ensure compliance with stringent quality requirements. Detailed impurity profiling not only safeguards product integrity but also supports the elucidation of degradation pathways and the optimization of synthetic processes.
Analytical method development: The availability of chemically pure impurity F allows analytical chemists to develop, validate, and refine chromatographic and spectrometric techniques for the separation and quantification of minor components in complex mixtures. Its inclusion in method validation protocols enhances the specificity, sensitivity, and robustness of high-performance liquid chromatography (HPLC), mass spectrometry (MS), and related techniques. This facilitates the reliable detection of trace-level impurities, which is essential for both batch release and long-term stability studies.
Process optimization: Studying the formation and behavior of atosiban impurity F provides valuable insights into the synthetic routes and degradation mechanisms of peptide manufacturing. By tracking the occurrence of this impurity under various reaction conditions, process chemists can identify critical control points, minimize unwanted byproduct formation, and improve overall process yields. This targeted approach to process optimization contributes to higher efficiency and cost-effectiveness in peptide production.
Stability studies: As a known degradation product, impurity F serves as an important marker in forced degradation and stability-indicating studies. Its deliberate introduction into stability protocols enables researchers to characterize the pathways by which atosiban and its formulations may degrade over time or under stress conditions. Understanding the kinetics and environmental factors influencing impurity formation aids in establishing appropriate storage, packaging, and shelf-life parameters for peptide-based products.
Regulatory compliance support: The use of well-characterized impurities such as impurity F is essential for meeting regulatory expectations regarding the identification, qualification, and quantification of related substances in pharmaceutical products. By incorporating this compound into analytical documentation and validation packages, manufacturers and contract laboratories can demonstrate comprehensive control over product quality. This supports regulatory submissions, facilitates audits, and provides assurance to stakeholders regarding the safety and consistency of peptide therapeutics throughout their lifecycle.
1. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
2. Cationic cell-penetrating peptides are potent furin inhibitors
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More